Amylyx Pharmaceuticals
AMLXAmylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Re …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2023-2025
All insider trades at Amylyx Pharmaceuticals
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 3/31/2025 | Sell | Klee, Justin B. | Co-Chief Executive Officer | $3.5 | $74,454 |
| 3/31/2025 | Sell | Cohen, Joshua B. | Co-Chief Executive Officer | $3.5 | $74,482 |
| 3/31/2025 | Sell | Mazzariello, Gina | Chief Legal Officer | $3.5 | $31,954 |
| 3/31/2025 | Sell | Bedrosian, Camille L. | Chief Medical Officer | $3.5 | $43,082 |
| 3/31/2025 | Sell | Frates, James M. | Chief Financial Officer | $3.5 | $37,806 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)